Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Nicholaos C. Bellos
Observed names:
Bellos Nicholaos C.,
N. Bellos,
Nicholaos Bellos,
Nicholaos C Bellos,
Nicholaos C. Bellos
Observed institutions:
University of North Carolina at Chapel Hill,
University of Southern California,
Chelsea and Westminster Hospital,
Gilead Sciences (United States),
The University of Texas Southwestern Medical Center
OpenAlex ID:
A5052106640
Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection
2008
·
Gerd Fätkenheuer
, Mark Nelson
, et al.
·
New England Journal of Medicine
·
367
Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment
2009
·
Kimberly Y Smith
, Parul Patel
, et al.
·
AIDS
·
226
Tenofovir Disoproxil Fumarate in Nucleoside-Resistant HIV-1 Infection
2003
·
Kathleen Squires
, Anton L. Pozniak
, et al.
·
Annals of Internal Medicine
·
200
SOLO
2004
·
Joseph C Gathe
, Prudence Ive
, et al.
·
AIDS
·
198
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial
2018
·
Jean-Michel Molina
, Kathleen Squires
, et al.
·
The Lancet HIV
·
153
A 96‐Week Comparison of Lopinavir‐Ritonavir Combination Therapy Followed by Lopinavir‐Ritonavir Monotherapy versus Efavirenz Combination Therapy
2008
·
D. William Cameron
, Barbara A. da Silva
, et al.
·
The Journal of Infectious Diseases
·
110
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial
2019
·
Jean-Michel Molina
, Kathleen Squires
, et al.
·
The Lancet HIV
·
99
First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America
2008
·
Benjamin Young
, Kathleen Squires
, et al.
·
AIDS
·
95
T‐1249 Retains Potent Antiretroviral Activity in Patients Who Had Experienced Virological Failure while on an Enfuvirtide‐Containing Treatment Regimen
2005
·
Jacob P. Lalezari
, Nicholaos C. Bellos
, et al.
·
The Journal of Infectious Diseases
·
95
Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults
2017
·
François Raffi
, Chloe Orkin
, et al.
·
JAIDS Journal of Acquired Immune Deficiency Syndromes
·
84
A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: Selection of thymidine analog regimen therapy (START II)*
2000
·
Joseph J. Eron
, Robert L. Murphy
, et al.
·
AIDS
·
81
Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients
2010
·
Kathleen E Squires
, Benjamin Young
, et al.
·
AIDS
·
65
Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials
2023
·
Chloe Orkin
, Jean-Michel Molina
, et al.
·
The Lancet HIV
·
36
ARIES 144 Week Results: Durable Virologic Suppression in HIV-Infected Patients Simplified to Unboosted Atazanavir/Abacavir/Lamivudine
2012
·
Kathleen E. Squires
, Benjamin Young
, et al.
·
HIV Clinical Trials
·
31
PDF
Abacavir Expanded Access Program for Adult Patients Infected with Human Immunodeficiency Virus Type 1
2002
·
Harold A. Kessler
, Judy Johnson
, et al.
·
Clinical Infectious Diseases
·
24
Lamivudine 300 mg QD Versus Continued Lamivudine 150 mg BID with Stavudine and a Protease Inhibitor in Suppressed Patients
2002
·
Sension Michael G.
, Bellos Nicholaos C.
, et al.
·
HIV Clinical Trials
·
10
Similar Efficacy of Raltegravir When Used With or Without a Protease Inhibitor in Treatment-Experienced Patients
2011
·
Daniel J. Skiest
, Calvin Cohen
, et al.
·
HIV Clinical Trials
·
6
PDF
P1171 Integrated Safety Analysis of Sofosbuvir-based Hcv Treatment Regimens From Phase 3 Studies
2014
·
S. Gordon
, W. Towner
, et al.
·
Journal of Hepatology
·
4
Efficacy and safety of switching suppressed patients with elevated triglycerides from lopinavir/ritonavir or fosamprenavir/ritonavir to atazanavir/ritonavir or darunavir/ritonavir based therapy: The LARD study
2012
·
Daniel J. Skiest
, Calvin Cohen
, et al.
·
HIV & AIDS Review
·
2
Twice‐Daily Trizivir versus Combivir‐Abacavir in Antiretroviral‐Experienced Adults with Human Immunodeficiency Virus‐1 Infection: A Formulation‐Switch Trial
2003
·
For the ESS40005 Study Team
, Margaret A. Fischl
, et al.
·
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
·
1
Background: Resistance to antiretroviral agents remains a lead- ing cause of treatment failure for patients infected with HIV-1.
2003
·
Kathleen Squires
, Anton Pozniak
, et al.
Show more works
View as search
Works count:
21
Citation count:
1,887
H-index:
15
I10-index:
16
Year
Topic
Type
